YOU MAY BE ENTITLED TO COMPENSATION AND DAMAGES FOR YOUR INJURIES – WE ARE AVAILABLE TO ASSIST YOU IN YOUR RECOVERY
Onglyza and Nesina May Increase the Risks of Pancreatic Cancer, Thyroid Cancer and Heart Failure
A FDA advisory committee voted to update the label for Onglyza to warn patients of an increased risk of heart failure. These drugs have also been linked to pancreatic cancer and thyroid cancer.
If you or a family member has taken Onglyza and/or Nesina and have been injured, you may be entitled to compensation.
- Our firm is vigorously pursuing this matter.
- Our clients have received millions of dollars in lawsuits involving defective drugs.
- No Charge or Obligation for Our Experienced Attorney Review
CONTACT US NOW! Do Not Delay As The Applicable Statute Of Limitations May Result In A Complete Bar To Your Claim Regardless Of Its
About Onglyza and Nesina
Onglyza (saxagliptin), manufactured by AstraZeneca and Bristol-Myers Squibb, and Nesina (alogliptin), manufactured by Takeda Pharmaceuticals, are approved by the FDA to help those with diabetes maintain a healthy blood sugar level. These drugs belong to a class called incretin mimetics, which stimulates the production of insulin to help regulate blood sugar in patients with type-2 diabetes.
The makers of Onglyza funded a study which found patients who used the drug had a higher rate of hospitalizations due to heart failure. In April 2015, an advisory committee to the FDA voted to update the label for Onglyza to add information regarding the increased risk of heart failure.
A March 2013 study showed a strong link between these diabetes medications and pancreatic cancer. This study also showed that those who had taken these medications had a pancreas that was 40% larger than normal and had a 6x increase of pre-cancerous cell growth and tumors. These tumors can become cancerous. In 2011, the FDA issued a safety warning after studies showed a higher rate of thyroid cancer in rodents taking incretin mimetics.